Seer, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 08, 2024 at 04:05 pm
Share
Seer, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.954 million compared to USD 1.31 million a year ago. Revenue was USD 3.07 million compared to USD 4.05 million a year ago.
Net loss was USD 20.68 million compared to USD 23.96 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.38 a year ago. Diluted loss per share from continuing operations was USD 0.32 compared to USD 0.38 a year ago.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
